Esophageal Squamous Cell Carcinoma - Network of Cancer Research

Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Non-Small Cell Lung Cancer

Afatinib is an Orally Active EGFR/HER2 Dual Inhibitor for Cancer Research

Louis Gilman August 17, 2023

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). These structurally related receptors…

Breast Cancer Esophageal Squamous Cell Carcinoma Esophagus Cancer

Conglobatin, an Orally Active Hsp90 Inhibitor, Disrupts Hsp90-Cdc37 Complex Formation

Louis Gilman March 18, 2021

Heat shock protein (Hsp) 90 is a chaperone protein. In addition to protecting cells by correcting misfolded proteins, Hsp90 also plays a key role in regulating the stability, maturation, and…

Afatinib is an Orally Active EGFR/HER2 Dual Inhibitor for Cancer Research

Conglobatin, an Orally Active Hsp90 Inhibitor, Disrupts Hsp90-Cdc37 Complex Formation

You Missed

BI 7446 is a STING Agonist for Immuno-oncology Research

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research